The END Fund raises and provides capital for programmes to control and eliminate neglected tropical diseases (NTDs). It also provides technical and strategic support for NGOs, governments, and various stakeholders to advance NTD treatment programmes and delivery.
The END Fund reports that 1.7 billion people worldwide need treatment for intestinal worms, most of them children. Neglected tropical diseases (NTDs) cause severe pain and long-term disability and lead to death for more than 170,000 people per year. Children who are infected suffer from malnutrition, cognitive impairment, stunted growth, and the inability to attend school. Many people who are infected are unable to work to provide for themselves or their families and are left in a cycle of poverty.
The END Fund mobilises resources from a diverse range of investors and directs them to partners who can deliver them where they will have the most impact. It focuses on delivering NTD treatments by:
More specifically, The END Fund:
As of 2022, The END Fund reports that its work has helped provide over 1.2 billion treatments since its founding in 2012, with 118 million treatments in 2021 alone.
The impact-focused evaluator Founders Pledge conducted an internal analysis of the cost-effectiveness of The END Fund’s deworming programme in 2023 with a favourable conclusion. The END Fund’s deworming programme was also previously one of our recommended charities due to GiveWell’s inclusion of it as a top-rated giving opportunity from 2016 to 2022. GiveWell’s decision to no longer recommend The END Fund’s deworming programme was not based on any shift in thinking about The END Fund, but rather a change in GiveWell’s top charity criteria.
Some research shows that deworming has positive effects on improved life outcomes like school attendance and income earnings. There is also some uncertainty surrounding findings that link deworming programmes to improved life outcomes — see GiveWell’s in-depth report on the case for mass deworming.